Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Proshares Trust (ZBIO) Other Non-Current Liabilities (2023)

Historic Other Non-Current Liabilities for Zenas BioPharma (ZBIO) over the last 1 years, with Q4 2023 value amounting to $20.3 million.

  • Zenas BioPharma's Other Non-Current Liabilities changed N/A to $20.3 million in Q4 2023 from the same period last year, while for Dec 2023 it was $20.3 million, marking a year-over-year change of. This contributed to the annual value of $20.3 million for FY2023, which is N/A changed from last year.
  • Per Zenas BioPharma's latest filing, its Other Non-Current Liabilities stood at $20.3 million for Q4 2023.
  • Zenas BioPharma's Other Non-Current Liabilities' 5-year high stood at $20.3 million during Q4 2023, with a 5-year trough of $20.3 million in Q4 2023.